ARCHIVES

CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans.

This article is from The Cancer Letter archive.

Vol. 30 No. 42 | November 5, 2004

Download PDF Visit The Full Archive

Related Articles

NCCN Also to Warn Doctors. Amgen’s Pledges to Disclose Future Results.

February 23, 2007

In Brief: Mansfield To Head NCI Radiation Research; Cowan Is Acting Chief, Medicine Branch

June 23, 1995

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

March 28, 2014

Regulatory Agencies: FDA Proposes “Treatment IDE” Funding Opportunities:

February 7, 1997

Zubrod To Retire as Miami Director; Baker Succeeds Brennan As Director Of Detroit Center

January 29, 1988

Construction Needs From NCI Said $40 Million Year For Four Years

June 9, 1978